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Abstract: Accumulating evidence suggests that brain metabolic changes may be associated with the pathophysiol-
ogy of schizophrenia. Both in vivo and in vitro studies have found glutamatergic and GABAergic abnormalities in 
different brain regions of individuals with schizophrenia. We report a longitudinal behavioral study in a methyl-
azoxymethanol acetate (MAM) rat model of schizophrenia at three different age periods: prepuberty, late-puberty 
and early-adulthood. MAM-treated rats showed stable hypolocomotive activity, anxiety and cognitive deficits from 
late-puberty to early-adulthood. Therefore we detected the metabolites changes of adult MAM-treated rats using an 
in vitro proton nuclear magnetic resonance (1H-NMR) method. In the MAM-treated rats, glutamate was increased 
in the thalamus and hypothalamus, glutamine was increased in the hippocampus and GABA was increased in the 
hippocampus and prefrontal cortex, while taurine showed a decrease in the striatum, temporal cortex and parietal 
cortex. These abnormalities may be helped further understanding the pathophysiology of schizophrenia.
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Introduction
Schizophrenia is regarded as a neurodeve- 
lopmental disorder characterized by positive 
symptoms, negative symptoms and cognitive 
deficits, which has clinical onset in late-puberty 
to early adulthood [1]. Because of ethical and 
practical limitations of human experimental 
biology, animal models are an important tool 
for investigating the pathophysiology and treat-
ment of neuropsychiatric diseases [2]. Methy- 
lazoxymethanol acetate (MAM) is a mitotoxin 
which can interfere with neurogenesis in corti-
cal and subcortical areas when it is adminis-
trated at embryonic day 17. As a neurodevelop-
mental model, there are a lot of evidences that 
the structural, functional and behavioral altera-
tions in the MAM model are consistent with 
those observed in schizophrenia [3, 4]. However, 
there is still no study that has explored how pre-
natal interference alters brain metabolic status 
after disease onset.
Accumulating evidences suggest that brain 
metabolic changes may be associate with the 
pathophysiology of schizophrenia [5]. Glutama- 
tergic and GABAergic metabolites are of partic-
ular interest which could stand for the majority 
of excitory and inhibitory neurotransmissions 
among brain metabolites. Evidence for the glu-
tamate hypothesis originated from the fact that 
administration of N-methyl-D-aspartate (NMDA) 
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receptor antagonists, such as phencyclindine 
(PCP) and ketamine, could induce the psycho- 
tic symptoms that resemble schizophrenia in 
healthy volunteers [6, 7]. Kim et al. first found 
decreased glutamate (Glu) concentration in the 
cerebrospinal fluid of schizophrenia patients 
using the fluorometric method [8]. Postmo- 
rtem analysis found abnormalities on density 
and subunit constitution of glutamatergic re- 
ceptor in the hippocampus and thalamus [9- 
11], and also reduced GABA-synthesizing en- 
zyme, mRNA and protein in schizophrenia [12-
14]. Proton magnetic resonance spectroscopy 
(1H-MRS) studies have reported elevated GABA 
and Glx (glutamate + glutamine) in the medial 
prefrontal cortex [15]. There is also evidence 
which showed that hypofunction of NMDA 
receptors on GABAergic neurons and abnormal 
metabolism of glutamatergic and GABAergic 
neurotransmission are associated with the 
pathophysiology of schizophrenia [16].
Additionally, taurine is a neurotransmitter and 
an inhibitory neuromodulator in the central ner-
vous system which could protect neurons from 
glutamate-induced neuronal excitotoxicity [17]. 
Through different types of calcium channels, 
taurine can antagonize the glutamate induced 
elevation of intracellular free calcium ion con-
centrations [17]. Studies using high-performan- 
ce liquid chromatography and gas chromato- 
graphy-mass spectrometry showed that the 
schizophrenia patients had significantly lower 
concentrations of taurine in cerebrospinal and 
plasma compared with the control subjects 
[18, 19]. However, another study using 1H-MRS 
found taurine to be elevated in the medial pre-
frontal cortex of schizophrenia patients [20].
Among the methods that detect metabolic 
alterations, 1H-MRS has been developed as a 
powerful tool to measure metabolites of the 
regional brain in schizophrenia with the majori-
ty focusing on patients in vivo. Due to limited 
resolution and time constraint, most studies 
commonly use the magnetic field strength of 
1.5 or 3 T [5, 21], in vivo 1H-MRS can only 
detect a few molecules and locate predeter-
mined voxels. However, based on previous find-
ings of brain metabolic changes in schizophre-
nia, the abnormalities were found in multiple 
brain regions. Therefore, a specific technique 
could be adopted to simultaneously detect the 
metabolites in different brain regions, and the 
brain regions most associated with the meta-
bolic abnormalities in schizophrenia could be 
selected. With much higher spectral resolution, 
the in vitro proton nuclear magnetic resonance 
(1H-NMR) can provide the specific metabolic 
information of different brain regions in the 
whole brain simultaneously, which can improve 
our understanding of the findings in vivo [22].
In this study, we selected three different age 
periods of MAM vs. saline treated rats to test 
behavioral alterations. At adult age, the 1H-NMR 
method was used to carry out the metabolo-
mics analysis of extracts from nine different 
brain regions. To our knowledge, this is the first 
time the neurochemical changes in multiple 
brain areas of MAM model with in vitro 1H-NMR 
have been explored. The findings in the current 
study may contribute to further investigations 
of the pathophysiology of this disease.
Materials and methods
Animals
All procedures in these experiments were in 
accordance with the guidelines of the Animal 
Care and Use Committees at the Wuhan 
Institute of Physics and Mathematics, Chinese 
Academy of Science. The pregnant Sprague 
Dawley dams were obtained from VITAL RIVER 
(Beijing, China). The dams were randomly treat-
ed with either MAM 22 mg/kg or vehicle (0.9% 
saline solution) intraperitoneally (i.p.) on gesta-
tional day 17 (day 0 was defined as the day of 
plug observed) [23, 24]. Pups were weaned 21 
days after birth, and the males were kept in 
groups of three individuals with unlimited 
access to a diet of pellets and water. Animals 
were housed in a room under controlled tem-
perature (21 ± 2°C) with a 12-h light/dark 
(lights at 8:00 am-8:00 pm) cycle. 
Animal behavioral studies
In order to investigate the alterations of behav-
iors during the animal’s growth, a list of animal 
behavioral experiments (Open field test, OFT; 
Morris water maze, MWM) of the MAM or saline 
treated male rats were studied in three differ-
ent age periods (n = 11 in each group), which 
are considered as prepuberty (PD32-39), 
late-puberty (PD50-57) and early-adulthood 
(PD80-87).
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Open field test (OFT): The apparatus used was 
a black box (100 × 100 × 30 cm3) with a video 
camera above the arena. The bottom of the box 
was divided into 25 (5 × 5) squares, and the 
central four squares were considered as the 
central zone. On the experimental day, a rat 
was placed in the center of the bottom, video 
recorded and timed at the same time. After 5 
min, the rat was returned to its home cage. The 
chamber was cleaned with 70% ethanol to 
avoid any information left before the next test. 
The total distance traveled, mean speed, 
entries to the center area and time spent in the 
center area were analyzed.
Morris water maze (MWM): The water maze 
apparatus was a circular black pool (diameter = 
180 cm, height = 50 cm) filled with water 
(approximately 24 ± 1.0°C). A platform (diame-
ter = 10 cm, height = 26 cm) was hidden 2 cm 
below the surface of the water in a fixed posi-
tion (the center of the southwest quadrant). 
The room contained several visual cues on the 
room walls. A computerized video system was 
utilized to record and analyze the behaviors of 
the rat during the experiment. 
The day before behavioral testing, the rats were 
exposed to the pool without the platform for 60 
s to adapt to the experiment. In acquisition trial, 
the rats were placed in the water facing the wall 
and free to swim until they found the platform 
and stayed on it for 3 s. If an animal failed to 
find the platform within 60 s, it was guided to 
the platform and remained for 10 s. Each rat 
was subjected to 4 trials per day for 4 days, and 
the starting position was changed in each trial 
(starting on the N side, followed by E, S, W 
sides). In probe trial, the 5th day of the experi-
ment, the platform was removed and the rats 
were allowed to swim freely for 90 s. Time to 
the platform (escape latency) in each acquisi-
tion trial and probe trial was calculated. 
Percentage time in the target quadrant (quad-
rant time) and the number of times the subject 
crossed the platform location (platform cross-
ing) were calculated during the probe trial.
1H-NMR studies 
Brain samples collection: After the behavioral 
studies in early-adulthood periods, the animals 
were anesthetized (sevoflurane) and micro-
waved (1.0 kw, 19 s) using a commercial head 
focused microwave machine (Tangshan Nano- 
source Microwave Thermal Instrument Manu- 
facturing Co. Ltd.) to prevent postmortem 
chemical changes [25]. The cooked brain tis-
sue was quickly removed from the skull and 
manually divided into nine different brain 
regions, such as midbrain (MID), thalamus 
(THA), hypothalamus (HYP), hippocampus (HIP), 
striatum (STR), temporal cortex (TC), prefrontal 
cortex (PFC), parietal cortex (PC) and occipital 
cortex (OC) according to the anatomical land-
marks [26, 27]. The tissues were placed into a 
2 ml pre-weighed EP tube, reweighed and 
immediately frozen in liquid nitrogen. At the 
end, all samples were stored in -80°C refrigera-
tor for further analysis.
Samples extraction: HCl/methanol (300 μL, 
0.1 M HCl) and ethanol (600 μL, 60%) were 
added separately to the samples and homoge-
nized twice (20 Hz, 90 s, Tissuelyser II, QIAGEN, 
Germany) [28]. The mixture was centrifuged 
(4°C, 11,000 g, 10 min) and the supernatant 
was placed into a 5.0 ml EP tube. The extrac-
tion process was repeated twice with 700 μl 
ethanol each time. All supernatants were col-
lected together and desiccated with the cen-
trifugal drying apparatus (Thermo Scientific 
2010, Germany) for 3 h. Samples were further 
dried with a freeze dryer for 24 h.
Phosphate buffer (pH = 7.2, 540 μL) and dou-
ble distilled water (60 μl, 120 mg/L 3-(Tri- 
methylsilyl) propionic-2, 2, 3, 3, d4 acid sodium 
salt (TSP, 269913-1G, Sigma Aldrich) in D2O) 
were added to dissolve the dried product and 
the mixture was vortexed for 30 s. TSP was set 
as the internal standard. The mixed solution 
was centrifuged (4°C, 14,000 g, 10 min) with 
high-speed centrifuge, and the supernatant 
(500 μl) was transferred to a 5 mm NMR tube 
for the 1H-NMR study.
1H-NMR study: One dimensional (1D) NMR 
spectra were acquired on a BrukerAvance III 
600 MHz NMR spectrometer equipped with an 
inverse cryogenic probe (BrukerBiospin, Ger- 
many). All data were collected at 298 K with a 
standard WATERGATE pulse sequence. The 
90° pulse length of each individual sample was 
adjusted to 10.1 μs. The scan was performed 
with the following parameters: Dummy scans 
(DS), 8; Acquisition scans (NS), 128; Acquisition 
time (AQ), 1.8 s; Relaxation delay (D1), 3.0 s; Spec- 
tral width, 20 ppm; Data points, 32 k. Finally, it 
took about 10 minutes for a sample to be load-
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ed and scanned. For a random sample, a series 
of two-dimensional (2D) NMR spectra were 
also collected to assign the metabolites in the 
1H-NMR spectra (online spectral databases). 
The 2D spectra include the following: 1H-1H 
correlation spectroscopy (COSY), J-resolved 
spectroscopy (JRES), 1H-1H total correlation 
spectroscopy (TOCSY), 1H-13C heteronuclear 
single quantum correlation (HSQC) and 1H-13C 
heteronuclear multiple bond correlation (HM- 
BC) 2D-NMR spectra data (online spectral 
databases). All the NMR data collections were 
completed using the TOPSPIN software (V3.0, 
BrukerBiospin, Germany). 
Statistical analysis
Behavioral experiments: For analysis of OFT, 
all data were analyzed using two-factor mix- 
ed ANOVA, with group (MAM vs. Control) as 
between-subject factor and age period (prepu-
berty, late-puberty, early-adulthood) as within-
subject factors. Post hoc analysis was per-
formed using the Bonferroni test. For analysis 
of the acquisition trial of MWM, all data of the 
four trials were used as an average on each 
training day. The effect of the prenatal MAM 
treatment on escape latency (s), was analyzed 
using two-way repeated measures (RM) ANOVA 
with days as RM. The Student’s t-test was used 
to further test the difference between the two 
groups on each training day. For analysis of the 
probe trial of MWM, all data were analyzed by 
two-factor mixed ANOVA, with group (MAM vs. 
Control) as between-subject factor and age 
period (prepuberty, late-puberty, early-adult-
hood) as within-subject factors. The criterion 
for statistical significance was a probability 
value of 0.05. All results are presented as 
means ± SEM.
NMR data: For Fourier transformation, all spec-
tra were firstly manually phased, baseline cor-
rected, and referenced to the internal standard 
TMSP (δ = 0) using Topspin software 3.2 
(Bruker Biospin, Germany). The raw data were 
automatically loaded into NMRSpec software 
[29], a tool using MATLAB code. Then, the peak 
alignment and integration were completed. 
Most amino acids were located in the region of 
1.1-4.2 ppm, thus the other regions were 
removed before spectral alignment. Further- 
more, ethanol was difficult to completely 
remove during the sample lyophilizing, that 
could affect the spectral analysis of the rele-
vant spectral regions (δ: 1.15-1.22 and 3.597-
3.687), thus the relevant ethanol signals were 
also discarded. All spectral data were divided 
into 0.04 ppm spectral buckets and automati-
cally integrated in NMRSpec. The bucketed 
spectral data and integrated areas were nor-
malized with the tissue weight and related peak 
area of TSP.
The absolute concentration (μmol/g wet weight) 
of the metabolite was calculated based on the 
following equation:
Cm = (Am*CTSP*VTSP*9)/(Rm*nH)
Where Am is the related peak area of the target 
metabolite; CTSP and VTSP are the concentration 
and volume of TSP; 9 is the number of protons 
in TSP; nH is the number of protons of the 
metabolites within the peaks area of Am; Rm is 
the ratio between the area of partial NMR sig-
nal of the selected metabolites during actual 
detection and the area of the whole proton sig-
nal in the standard spectrum. During sample 
detection, many signals overlapped, thus it was 
impossible to use them to calculate the abso-
lute concentration. It was better to select a 
pure signal which did not overlap with other sig-
nals or part of the related signal. For example, 
Rm values of the metabolites Asp, taurine, Gly 
and creatine were equal to 1, whereas the 
signals of NAA (0.5871), GABA-4 (0.5728), 
Glu-4 (0.9001), Gln-4 (0.3901) and myo-instol 
(0.4933) overlapped with the other signals.
Data analysis was performed using SPSS soft-
ware (Version 22) and codes in MATLAB. 
Student’s t-test were employed to determine 
the significant differences in metabolite con-
centrations. Probability value of 0.05 was con-
sidered statistically significant. Metabolite con-
centrations were presented as means ± SEM.
Results
Behavioral experiments
Open field test: For the spontaneous locomotor 
activity analysis, the total travel distance was 
significantly reduced in MAM rats (Figure 1A, F 
= 19.578, P<0.001). There was no age period 
effect as well as group × age period interaction 
displayed. The group difference was present in 
late-puberty (P<0.001) and early-adulthood (P 
= 0.004) compared to control rats following 
post hoc analysis. However, there was no sig-
Brain metabolites alterations in a schizophrenia model
5923 Am J Transl Res 2019;11(9):5919-5931
nificant difference between the two groups in 
prepuberty (P = 0.257). Total travel distance of 
MAM rats was significantly reduced in late-
puberty (P = 0.045) and early-adulthood (P = 
0.035) compared to prepuberty, but there was 
no difference between late-puberty and early-
adulthood. There was no difference in total 
travel distance between any two age periods in 
control rats. Thus, MAM rats showed impair-
ment in spontaneous locomotor activity from 
late-puberty to early-adulthood.
For the anxiety reactivity analysis (Figure 1B 
and 1C), MAM rats showed less time spent in 
the center area (F = 26.696, P<0.001) and 
fewer entries to the center area (F = 31.251, 
P<0.001). There was no age period effect as 
well as group × age period interaction dis-
played. Post hoc analysis showed that the 
group difference was consistently present in 
the three age periods: prepuberty, time spent 
in the center area (P<0.001), entries of center 
area (P<0.001); late-puberty, time spent in the 
center area (P = 0.012), entries to center area 
(P<0.001); early-adulthood, time spent in the 
center area (P = 0.012), entries to center area 
(P = 0.031). There was no difference between 
any two age periods in MAM and control rats, 
indicating that MAM rats exhibited stability of 
anxiety state in all age periods.
Morris water maze: In the acquisition trial, MAM 
rats showed deficits in spatial learning ability 
from late-puberty to early-adulthood, but not in 
prepuberty (Figure 2A). The two-way ANOVA 
with day as repeated measures revealed an 
effect of group on escape latency in late-puber-
ty (F = 0.323, P = 0.004) and early-adulthood (F 
= 7.250, P = 0.015), but not in prepuberty (F = 
0.148, P = 0.704). Further analysis of each 
training day using Student’s t test, showed 
that MAM rats spent more time to find the plat-
form on day 1 (F = 0.777, P = 0.002) in late-
puberty, day 2 (F = 3.960, P = 0.016) and day 4 
(F = 7.274, P = 0.002) in early-adulthood. There 
was no difference on any day in prepuberty. The 
two-way ANOVA with day as repeated measure-
ments also showed an effect of training days in 
three age periods (prepuberty, F = 4.529, P = 
0.006; late-puberty, F = 5.331, P = 0.003; ear-
ly-adulthood, F = 12.792, P<0.001), which indi-
cates the learning process of the test. There 
was no interaction between groups and training 
days in any age periods. 
In the probe trial, MAM showed a slight differ-
ential in reference memory in early-adulthood. 
Overall analysis showed MAM rats spent more 
time to find the platform (F = 6.372, P = 0.003, 
Figure 2B). An age period effect was present (F 
= 6.372, P = 0.003), but not a group × age 
period interaction (F = 0.439, P = 0.647). Post 
hoc analysis revealed no group difference in 
the three age periods (prepuberty, P = 0.421; 
late-puberty, P = 0.184; early-adulthood, P = 
0.951). Overall analysis displayed no group 
effect on the time of swimming in the target 
quadrant (F = 0.727, P = 0.397, Figure 2C). 
There was also no age period effect (F = 1.094, 
P = 0.342) and group × age period interaction 
(F = 2.718, P = 0.074). Post hoc analysis 
showed that there was group difference pres-
ent in early-adulthood (P = 0.019). MAM rats 
spent less time in crossing the platform loca-
tion (F = 4.891, P = 0.031, Figure 2D). An age 
period effect (F = 10.028, P<0.001) was also 
found, but no group × age period interaction (F 
= 0.462, P = 0.633). The difference was pres-
ent in early-adulthood (P = 0.049) by the post 
hoc analysis. 
Figure 1. Effect of MAM vs. saline treatment on performance in the open field test (OFT) at three age periods. Each 
column represents the mean (± S.E.M.) on the experiment day of OFT. *P<.05 compared with control rats at the 
same age period; **P<.01 compared with control rats at the same age period. ***P<.001 compared with control rats 
at the same age period.
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NMR data
In the current study, there were nine different 
brain regions involved. In order to show the 
results clearly, only a sample from the brain 
region (occipital cortex) were selected for illus-
tration. At first, the metabolites in the 1H-NMR 
spectrum were identified using related pub-
lished works and 2D-NMR spectra. The identifi-
cation of these metabolites is shown in (Figure 
3). Furthermore, the average NMR spectrum of 
the extracts in the represented brain region 
(occipital cortex) in the MAM-treated and con-
trol groups were also calculated and illustrated 
(Figure 3). During the extraction of the brain 
samples, methanol and ethanol were involved, 
which were detected using 1H-NMR methods. 
During the lyophilization procedure, these two 
chemicals were evaporated. However, the re- 
sults showed that it was very difficult to totally 
erase them. Thus, the NMR signal regions relat-
ed to ethanol and methanol were discarded for 
further analysis. 
In order to primarily estimate the difference of 
the metabolites in different brain regions, the 
differences of the average 1H-NMR spectra in 
the MAM-treated and control groups were cal-
culated (Figure 4). The different metabolites in 
these brain regions were identified. However, 
there is no information of the standard devia-
tion of these metabolites in this figure. Thus, it 
was very difficult to verify the major differences 
between brain regions in the MAM group com-
pared with the control group. 
Statistical analysis of the metabolites
The absolute concentrations of all detected 
metabolites in different brain regions were cal-
Figure 2. A. Effect of MAM vs. saline treatment on performance in the acquisition trial of the Morris water maze 
(MWM) at three age periods. The two-way ANOVA with day as repeated measures revealed an effect of group on 
escape latency in late-puberty (F = 7.250, P = 0.015) and early-adulthood (F = 8.603, P = 0.008). Each point repre-
sents mean (± S.E.M.) of the four trials on the same experiment day. *P<.05 compared with control rats on the same 
experiment day by Student’s t test; **P<.01 compared with control rats on the same experiment day using Student’s 
t test. B-D. Effect of MAM vs. saline treatment on performance in the probe trial of the Morris water maze at three 
age periods. Each column represents the mean (± S.E.M.) of four consecutive trials. *P<.05 compared with control 
rats at the same age period.
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Figure 3. The average normalized 1H-NMR spectra of the metabolites of occipital cortex of MAM vs. saline treat-
ment. Red line: control; black line: MAM. Note: Lowercase, position of the hydrogen signal which is connected with 
the carbon position; Lac, lactate; Myo, myo-institol; Cre, creatine; Asp, aspartic acid; Ala, alanine; Glx, glutamine + 
glutamate; EtoH, ethanol; Gly, glycine; Tau, taurine; GABA, gamma amino acid butyric acid; NAA, N-aceytl aspartate; 
Gln, glutamine; Glu, glutamate.
Figure 4. Differences in 1H-NMR spectra of the metabolites of different brain regions of MAM vs. saline treatment. 
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culated. Then the metabolites in different brain 
regions of these two different groups were com-
pared. For precise analysis, group differences 
were found in Glu, Gln, GABA and taurine. Glu 
was significantly increased in the thalamus (F = 
0.476, P = 0.004) and hypothalamus (F<0.001, 
P = 0.025, Figure 5A). Gln was elevated in 
the hippocampus (F≤0.001, P = 0.015, Figure 
5B). GABA was found raised in the hippocam-
pus (F = 0.040, P = 0.029) and the prefrontal 
cortex (F = 0.201, P = 0.203) of MAM rats 
(Figure 5C). Taurine decreased in the striatum 
(F = 0.044, P = 0.026), temporal cortex (F = 
5.438, P = 0.020) and parietal cortex (F = 
0.067, P = 0.028, Figure 5D).
Discussion
Behavioral patterns of MAM-treated rats
Gestational MAM exposure model has been 
suggested to produce similar behavioral abnor-
malities to those seen in schizophrenia. A previ-
ous study screened the MAM-treated rats in 
three different age periods: prepuberty (PD28-
42), late-puberty (PD56-70) and adulthood 
(PD98-112). The results indicated that the 
MAM rats had elevated locomotor activity in 
late puberty and adulthood, but not in prepu-
berty. The anxiolytic effect had different age 
patterns which was present in prepuberty and 
adulthood, but had disappeared in late puberty 
[30]. Another study found that MAM rats had 
the same locomotor activity with control rats in 
late-puberty (PD58-60) [31]. Elevated anxiety-
like behaviors of MAM rats were observed both 
in peripuberty [32] and adulthood [33] in other 
studies. However, there are few studies that 
confirmed whether the MAM model, like schizo-
phrenia, had onset in late-puberty or adult-
hood. Our findings are consistent with the clini-
cal observation that anxiety is highly prevalent 
in schizophrenia patients [34]. In the current 
study, MAM-treated rats showed hypoactivity 
from late-puberty to early-adulthood and hei- 
ghtened anxiety levels throughout the three 
age periods. These abnormalities might be cor-
related to hypersensitivity to stress [35] around 
puberty and resulted in the dopaminergic hyper 
responsivity which occurs in adulthood [32].
Cognitive deficits are believed to be core symp-
toms of schizophrenia. One study assessed 
MAM rats on an attentional set-shifting task 
which is a rodent analog of the Wisconsin card 
sort task. They found that MAM rats required 
Figure 5. Differences of metabolite concentration in nine brain regions of MAM vs. saline treatment. Each column 
represents the mean (± S.E.M.) of metabolite concentration of each group in certain brain region. *P<0.05 com-
pared with control rats at the same brain region; **P<.01 compared with control rats at the same brain region. 
***P<.001 compared with control rats at the same brain region.
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more time to learn the task [36]. Furthermore, 
another study examined the performance on 
Morris water maze of juvenile (PD12-21) and 
adolescent (PD28-45) MAM-treated rats. Both 
groups presented deficits in learning the loca-
tion of the platform [37]. In the present study, 
we found MAM-treated rats had similar perfor-
mance compared with the control during prepu-
berty, but the spatial learning ability were 
impaired from late-puberty and persisted in 
early-adulthood.
Overall, the behavioral abnormalities indicate 
that the MAM rats were in a relatively constant 
onset state from late-puberty to early-adult-
hood. This provided favorable evidence for our 
further study of metabolic changes using the 
MAM treated animal model. 
Metabolic changes in adult MAM-treated rats
Glutamatergic and GABAergic metabolites: The 
glutamate hypothesis of schizophrenia high-
lighted that NMDA receptor hypofunction might 
be a key mechanism that could help explain 
major clinical and pathophysiological aspects 
of schizophrenia [38]. The NMDA receptor hy- 
pofunction was associated with reduced parv-
albumin-containing GABA interneurons [39], 
leading to the imbalance between neuronal 
excitation and inhibition [40, 41], which may 
contribute to the disinhibition of cortical excit-
atory neurons resulting in excess glutamate 
release [41]. Mice with reduced expression of 
NMDA receptor manifested schizophrenia-like 
symptoms, and these kinds of symptoms can 
be alleviated by haloperidol or clozapine [42]. 
The long-time treatment with antipsychotic 
drugs could induce adaptive changes on gluta-
mate receptor expression in different brain 
regions of rats [43]. Postmortem analysis found 
reduction of glutamate in the hippocampus and 
prefrontal cortex [44] and alteration of the den-
sity and subunit constitution of glutamate 
receptor in the thalamus and hippocampus of 
schizophrenia patients [9-11]. A recent meta-
analysis which included 59 in vivo 1H-MRS 
studies revealed that there was a broad eleva-
tion of glutamatergic metabolites (glutamate, 
glutamine or glutamate plus glutamine) across 
several brain regions of schizophrenia patients 
and individuals at high risk, such as the thala-
mus, basal ganglia, medial frontal cortex and 
medial temporal cortex [45]. 
GABA is the main inhibitory neurotransmitter 
which is formed by the decarboxylation of gluta-
mate catalyzed by glutamate decarboxylase 
(GAD). Postmortem analysis found a subclass 
of GABA interneurons in the prefrontal cortex 
with significant low expression of GAD67 mRNA 
[13], which is consistent with other studies [12, 
14]. However, in 1H-MRS studies, there have 
been inconsistent results of GABA levels in 
schizophrenia individuals, with reports showing 
a reduction [46], unchanged [47, 48] and eleva-
tion [15, 49, 50], mainly located in the striatum, 
dorsal caudate nucleus, anterior cingulate, 
medial prefrontal cortex, temporal cortex, pari-
etal cortex and occipital cortex. With the in vitro 
1H-NMR method, we observed elevated GABA 
concentrations in the hippocampus and pre-
frontal cortex of MAM-treated rats. Our result is 
not exactly consistent with these former post-
mortem findings. That might be due to two main 
factors: the postmortem metabolite changes in 
the bio-system and the different living systems. 
However, all findings support that the GABA dis-
orders do occur in schizophrenia. 
Taurine: Increasing evidences suggest that the 
taurine-induced neuroprotective effect may be 
mediated by its antagonism to the glutamate-
induced excitotoxicity [17]. In an analysis of a 
rodent model of maternal immune activation 
(MIA) which is associated with schizophrenia, 
taurine was significantly reduced in hippocam-
pus of the adult offspring [51]. Moreover, in 
another MIA model with longitudinal observa-
tion, the reduction of taurine in the prefrontal 
cortex was found in adult offspring but not ado-
lescent offspring [52]. In vitro 1H-MRS study 
that used a rodent model of neonatal maternal 
deprivation revealed increased taurine in the 
hippocampus and prefrontal cortex, which 
reflect that the increased taurine might protect 
the neonatal brain after more severe damage 
[53]. At present, fewer taurine in vivo 1H-MRS 
studies have been reported, which only found 
elevated taurine in plasma [54] and the medial 
prefrontal cortex [20] of schizophrenia individu-
als. Our results suggest that taurine is signifi-
cantly reduced in the striatum, temporal cortex 
and parietal cortex of adult MAM-treated rats, 
this could probably be a decompensation state 
for excess glutamate. 
Abnormal metabolic state in corticolimbic sys-
tem: Our findings revealed that there was meta-
Brain metabolites alterations in a schizophrenia model
5928 Am J Transl Res 2019;11(9):5919-5931
bolic dysfunction in the corticolimbic system, 
such as the thalamus, hypothalamus, hippo-
campus, striatum, prefrontal cortex, temporal 
cortex and the parietal cortex. Structural 
changes in the corticolimbic system are impor-
tant features of schizophrenia. In this pathway, 
a major function of the NMDA receptor is to 
drive GABA interneurons, thus maintaining the 
inhibition of primary neurons in the limbic sys-
tem. NMDA receptor antagonists could inhibit 
the activation of GABA interneurons, which in 
turn could increase glutamate release [55] and 
lead to excessive excitatory activity release 
[56]. Further, evidence showed that the sensi-
tivity to NMDA receptor antagonists of rats 
developed during adolescence and continued 
into early adulthood [56] and NMDA receptor 
hypofunction was present in adolescence of 
the MAM model [57], which suggests that early 
developmental interference with the nervous 
system does not begin to take effect until ado-
lescence, which is consistent with our findings 
of behavioral changes. We postulate that the 
impairment of the NMDA receptor, which was 
caused by interference during the early devel-
opmental period, damaged GABAergic neurons, 
which led to the disinhibitory effect on down-
stream neurons. In the beginning, the nervous 
system could compensate for these damages 
through some mechanisms, and taurine might 
be one of these compensatory mechanisms. 
However, with the continuous maturation of the 
nervous system, the level of metabolites in the 
brain gradually become a decompensation 
state, as we observed with the elevation of Glu, 
Gln, GABA and the reduction of taurine, which 
eventually leads to damage of the cortical lim-
bic system. The mechanism by which the imbal-
ance in brain function and metabolic status 
and the role played in the pathophysiology of 
schizophrenia needs further research.
According to our experimental design, the 
detection of metabolites cannot be realized in 
prepuberty and late-puberty stage. Thus, we 
did not conduct dynamic monitoring of meta-
bolic alterations during the growth process. In 
future experiments, we will conduct multi-point 
monitoring to better explain this problem.
The present study demonstrated the effect of 
gestational exposure to MAM on the behavioral 
changes in different developmental periods 
and the metabolic alteration in different brain 
regions of adult rats. MAM-treated rats showed 
significant hypoactivity and high levels of anxi-
ety mainly from late-puberty to early-adulthood, 
and slightly cognitive impairment in early-adult-
hood. Metabolic analysis of adult MAM-treated 
rats showed Glu was increased in the hypothal-
amus and thalamus, GABA was increased in 
the prefrontal cortex and hippocampus, and 
Gln was increased in the hippocampus. How- 
ever, taurine showed a significant decrease in 
the striatum, temporal cortex and parietal cor-
tex. These findings may have some significance 
when studying how metabolic abnormalities in 
different brain regions of schizophrenia patients 
are involved in the pathophysiological mecha-
nism of the disease. In conclusion, the behav-
ioral changes of MAM rats, as a neurodevelop-
mental model, manifested in a time-dependent 
pattern and the metabolic changes in the corti-
colimbic system could be critical to the patho-
physiology of schizophrenia.
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